Ustekinumab Biosimilar is a monoclonal antibody commercialized by Rani Therapeutics, with a leading Phase I program in Psoriatic Arthritis. According to Globaldata, it is involved in 1 clinical trial, which was completed. GlobalData uses proprietary data and analytics to provide a complete picture of Ustekinumab Biosimilar’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Ustekinumab Biosimilar is expected to reach an annual total of $96 mn by 2039 globally based off GlobalData’s Revenue Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Ustekinumab Biosimilar Overview

Ustekinumab biosimilar is under development for the treatment of psoriasis, psoriatic arthritis, ulcerative colitis, crohn’s disease. The drug candidate is an human IgG1kappa monoclonal antibody. It is administered through oral route in the form of capsule. It acts by targeting the p40 subunit of the cytokines IL-12 and IL-23. It is being developed based on RaniPill platform.

Rani Therapeutics Overview

Rani Therapeutics, a subsidiary of Rani Therapeutics Holdings Inc, is a clinical-stage biotherapeutics company. It has developed a technology for the oral delivery of biologics. The company’s pipeline products include RT-101, RT-102, RT-105, RT-110 and RT-111. Its product’s therapeutic areas include neuroendocrine tumors (NETs), acromegaly, osteoporosis, psoriatic arthritis, hypoparathyroidism and psoriasis. The company conducts research to develop its approach and technology through collaborations with life sciences laboratories. Its technology has the potential to transform the RaniPill capsule injecting the drug into the intestinal wall. Rani Therapeutics is headquartered in San Jose, California, the US.

For a complete picture of Ustekinumab Biosimilar’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.